Research Article

Aldose Reductase Inhibitor Protects against Hyperglycemic Stress by Activating Nrf2-Dependent Antioxidant Proteins

Kirtikar Shukla, Pabitra Bikash Pal, Himangshu Sonowal, Satish K. Srivastava, and Kota V. Ramana

Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77555, USA

Correspondence should be addressed to Kota V. Ramana; kvramana@utmb.edu

Received 31 March 2017; Revised 15 May 2017; Accepted 28 May 2017; Published 27 June 2017

1. Introduction

Hyperglycemia is a major contributor to inflammation, apoptosis, profound vasodilation, tissue damage, and dysfunction in patients with diabetes mellitus [1]. The cytotoxicity of hyperglycemia is mediated by the increase in reactive oxygen species (ROS) which activate NF-κB and AP1 that results in the transcription of inflammatory cytokines [2]. Our recent studies indicate that inhibition of the polyol pathway enzyme aldose reductase (AR) prevents cytokine- and hyperglycemia-induced increase in inflammatory markers in macrophages, vascular cells, and diabetic mice [3, 4] by preventing the activation of NF-κB and AP1-induced proinflammatory signals [3, 5]. We have shown that preincubation with AR inhibitor prevents hyperglycemia- and cytokine-induced proliferation of vascular cells and apoptosis of macrophages [6–8]. While these studies indicate that inhibition of AR could prevent oxidative stress-induced inflammatory response, the mechanism(s) by which inhibition of AR prepares the cells against oxidative stress is not known.

Previous studies indicate that transcription factor nuclear factor-erythroid-2-related factor 2 (Nrf2) regulates a battery of cytoprotective genes which maintain cellular redox homeostasis. Nrf2 binds to the antioxidant response element (ARE) and transcriptionally regulates the gene expression of several antioxidant and phase II detoxifying enzymes including hemeoxygenase-1 (HO1), NAD(P)H-quinone dehydrogenase 1 (NQO1), γ-glutamylcysteine synthetase (GCS), glutathione S-transferases (GSTs), and AR [9]. Generally, under nonstress conditions, Nrf2 complexes with an adaptor protein, Keap1, which is a regulator of the proteasomal degradation of Nrf2. However, under stress conditions, Nrf2 dissociates from Keap1 and translocates to the nucleus and transcribes the genes responsible for defense against stress. Thus, it has been well established that activation of the Nrf2 pathway in response to oxidative stress protects the cells and tissues from oxidative injury [10].
Although our previous studies indicate that AR inhibition prevents hyperglycemia-induced NF-κB-dependent inflammatory signals, it is not known how AR inhibition increases the resistance of cells to withstand oxidative stress stimuli initiated by hyperglycemia. Therefore, in this study, we examined our hypothesis that AR inhibition promotes the activation of Nrf2-mediated cytoprotective pathways that protect cells against hyperglycemic stress. Our results suggest that AR inhibitor fidestat increases the expression as well as the DNA-binding activity of Nrf2 in Thp1 monocytes. In addition, fidestat increased the expression of Nrf2 downstream target proteins such as HO1 and NQO1 in Thp1 cells and heart and kidney tissues of STZ-induced diabetic mice. AR inhibitor also prevented the expression of antioxidant enzymes such as SOD and catalase. Collectively, our results demonstrate that AR inhibition protects the cells against hyperglycemia-induced changes in the cell viability by activating Nrf2/HO1-mediated antioxidative pathway, which could also account for the anti-inflammatory effects of AR inhibitors in diabetes.

2. Materials and Methods

2.1. Materials. RPMI-1640, penicillin/streptomycin, and fetal bovine serum (FBS) were purchased from Invitrogen. Antibodies against Nrf2 were obtained from Santa Cruz. Antibodies against KEAP1, HO1, NQO1, phospho-AMPKα1, AMPKα1, GAPDH, and histone H3 were purchased from Cell Signal Inc. Fidestat was obtained from Lliwel Therapeutics Inc., USA. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) and other reagents used in Western blot analysis were obtained from Sigma. HO1 assay kit was purchased from Abcam. Nrf2 transcription factor binding assay and superoxide dismutase activity assay kits were purchased from Cayman Chemicals. Catalase activity was determined spectrophotometrically using hydrogen peroxide (30%) (Sigma-Aldrich).

2.2. Cell Culture and Treatment. Human Thp1 monocytic cells were obtained from the American Type Culture Collection (ATCC) and cultured in RPMI-1640 medium supplemented with 10% FBS and penicillin/streptomycin at 37°C in a humidified atmosphere of 5% CO₂. Prior to treatment, cells were serum-starved in the respective medium containing 0.1% FBS ± fidestat (10 μM) for 14 h and further stimulated with high glucose (25 mM; 19.5 mM glucose was added to 5.5 mM glucose containing media) for different time intervals.

2.3. Cell Viability. Cell viability was determined using a standard MTT assay [11]. Briefly, Thp1 cells were growth arrested in 0.1% FBS containing RPMI medium. Cells were preincubated with fidestat (10 μM) for overnight (14 h) at 37°C followed by incubation with HG (25 mM) for another 48 h. At the end of incubation period, cells were incubated with 10 μl MTT reagent (5 mg/ml) for 4 h at 37°C. The formazan crystals formed by the viable cells were solubilized by the addition of 100 μl DMSO. Absorbance was measured at 570 nm using a microplate reader. Cell viability was also examined by counting the live and dead cells using a hemocytometer [6]. AR activity (mU/mg protein) was measured spectrophotometrically using glyceraldehyde as a substrate [6]. Nrf2 DNA binding activity was determined by Nrf2 transcription factor assay kit as per the manufacturer’s instructions (Cayman Chemical).

2.4. Immunoblot Analysis. Nuclear and cytoplasmic proteins from the treated cells were isolated using a nuclear extraction kit (Cayman Chemicals). Protein concentration in the extracts was measured with Bradford reagent (Bio-Rad). Equal amount of proteins were subjected to 12% SDS-PAGE electrophoresis followed by Western blot analysis using specific antibodies against Nrf2, Keap1, HO1, NQO1, AMPK, histone H3, and GAPDH. The antigen-antibody complexes were detected by enhanced Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific). Membranes were stripped with Restore TM PLUS stripping buffer (Thermo Scientific) and used for reprobing with other antibodies or loading controls.

2.5. Ablation of Nrf2 by siRNA. Thp1 cells cultured in RPMI 1640 medium containing 10% FBS were incubated with Nrf2-siRNA (120 nM) or siRNA negative control with HiPerFect Transfection Reagent as per the manufacturer’s instructions (Qiagen, USA). The cells were incubated in a humidified CO₂ incubator for 48 h at 37°C. Silencing of Nrf2 was determined by Western blotting.

2.6. Quantitative RT-PCR Analysis of HO1 mRNA. Total RNA was isolated from the treated cells using TRIzol reagent and was quantified by using a nanodrop spectrophotometer (NanoDrop Technologies). TaqMan reverse transcription reagents kit was used for the synthesis of cDNA from total RNA (Life Technologies). Q-PCR amplifications (performed in triplicate) were performed by using 1 μl of cDNA using the iTaq Universal SYBR Green Supermix (Bio-Rad). Housekeeping gene GAPDH was used as a normalizer. ABI Prism 7500 Sequence detection system used forward: 5′-C GGGCCAGCAACAAAGTG-3′, and reverse: 5′-CCAGAA AGCTGAGTGTAAGGACC-3′ was used for qPCR analysis of HO1 gene.

2.7. Determination of HO1 and Nrf2 in STZ-Induced Diabetic Mice. Seven-week-old C57BL/6 male mice were purchased from Envigo. Diabetes was induced in mice by injecting a single dose of streptozotocin (STZ; 165 mg/kg, i.p.) and blood glucose levels were measured by a glucometer (True Metrix). The mice with blood glucose levels >400 mg/dl were selected and randomly divided into diabetic and diabetic + fidestat groups. Fidestat (10 mg/kg/day, i.p.) was administered to diabetic mice, and the animals were euthanized on day 3.

2.8. Statistical Analysis. Data are presented as mean ± SD. The p values were determined using the unpaired Student’s t-test (GraphPad Prism software) and a p value of <0.05 considered as statistically significant.
3. Results

3.1. AR Inhibition Prevents HG-Induced Thp1 Cells Viability. The effect of AR inhibition on HG-induced Thp1 cells viability was examined by measuring the live and dead cell counts as well as MTT absorbance. The data shown in Figure 1(a) indicates that HG treatment of Thp1 cells decreased the number of live cells and increased the number of dead cells indicating that HG decreases Thp1 cell viability. However, pretreatment of Thp1 cells with AR inhibitor prevented the HG-induced decrease in the Thp1 cell viability. Similar results were observed when we measured the cell viability by MTT assay (Figure 1(b)). The data shown in Figure 1(c) also indicates that AR activity was significantly increased in the HG-treated Thp1 cells and fidaestat prevented it. These results thus suggest that AR inhibition prevents HG-induced decrease in the cell viability of Thp1 cells.

3.2. AR Inhibitor Increases the Expression of Nrf2. To examine how pretreatment of cells with AR inhibitor prevents HG-induced decrease in Thp1 cell viability, we examined the effect of AR inhibitor on the expression of Nrf2. Pretreatment of Thp1 cells with fidaestat alone or HG alone induced Nrf2 expression in a time-dependent manner. Further, preincubation of cells with fidaestat followed by incubation with HG significantly augmented the HG-induced increase in the expression of Nrf2 (Figure 2(a)). Similarly, treatment of Thp1 cells with HG decreased the expression of Keap1, a negative regulator of Nrf2 and preincubation with fidaestat, followed by HG decreased the expression of the Keap1 protein (Figure 2(a)). We next examined the effect of AR inhibitor on Nrf2 DNA binding activity in Thp1 cells. Nrf2 transcriptional activity increased in the fidaestat-treated Thp1 cells in a time-dependent manner as compared to that in control cells (Figure 2(b)). Further, fidaestat augmented the HG-induced Nrf2 transcriptional activity in Thp1 cells. These results thus suggest that preincubation of cells with AR inhibitor prepares the cells against oxidative insult by inducing the expression of Nrf2.

3.3. AR Inhibition Increases the Antioxidative Protein Expressions in Thp1 Cells. We next examined the effect of AR inhibitor on the expression of various Nrf2-dependent antioxidative proteins. Results shown in Figure 3(a) indicate that fidaestat alone or HG alone increased the levels of antioxidant proteins such as HO1 and NQO1 in Thp1 cells. Further, pretreatment with fidaestat followed by HG synergistically increased the HO1 and NQO1 protein expressions in Thp1 cells (Figure 3(a)). Similarly, AR inhibitor also increased the levels of HO1 in Thp1 cell lysates (Figure 3(b)). Furthermore, mRNA expression of HO1 increased significantly in cells treated with HG in the presence of fidaestat as compared to HG- or fidaestat-treated cells (Figure 3(c)). Furthermore, AR inhibitor also significantly increased the HG-induced SOD as well as catalase activities in Thp1 cells (Figures 3(d) and 3(e)). Thus, our results indicate that pretreatment of Thp1 cells with fidaestat enhances the antioxidant status of the cells as a defense against hyperglycemic stress.
3.4. Effect of AR Inhibitor on HG-Induced Cell Viability in Nrf-2-Knockdown Thp1 Cells. To examine the effect of Nrf2 on AR-regulated cell growth, we determined the Thp1 cell viability in the Nrf2-siRNA knockdown cells in the absence and presence of fidarestat. Incubation of Nrf2 knockdown cells with HG (25 mM) significantly increased cell death of Thp1 cells when compared to that of control cells (Figure 4). Further, fidarestat prevented the HG-induced Thp1 cell death in control siRNA-transfected cells but not in the Nrf2-siRNA-transfected cells, suggesting that fidarestat prevents Thp1 cell viability by increasing the Nrf2 expression.

3.5. AR Inhibitor Increases the Expression of Nrf2 and HO1 in Mouse Diabetic Heart and Kidney Tissues. We next examined the effect of fidarestat on the expression of antioxidant proteins, HO1, and Nrf2 in STZ-induced diabetic mouse heart and kidney tissues. Similar to data shown in the Thp1 cells, AR-inhibitor (fidarestat) also augmented the STZ-induced increase in the expression of Nrf2, HO1, and NQO1 in the heart and kidney homogenates of mice (Figure 5).

3.6. AR Inhibitor Regulates HG-Induced Phosphorylation of AMPK-α1 in Thp1 Cells. Since AMPK-α1 activation has been shown to activate Nrf2 signals, we next investigated the effect of fidarestat on HG-induced AMPK-α1 activation in Thp1 cells. Our results shown in Figure 6(a) indicate that fidarestat increased the HG-induced phosphorylation of AMPK-α1 in Thp1 cells. Further, to investigate the effect of Nrf2
on AMPK-α1 activation, Nrf2-siRNA-transfected Thp1 cells were stimulated with HG ± fidarestat and examined AMPK-α1 activation. The results shown in Figure 6 indicate that HG-induced increase in the phosphorylation of Nrf2 in the absence of fidarestat. However, pretreatment of fidarestat to the Nrf2 knockdown cells did not show any

**Figure 3:** AR inhibitor induces the expression of Nrf2-dependent antioxidant enzymes in HG-treated Thp1 cells. Thp1 cells were pretreated with fidarestat for 14 h followed by incubation with HG (25 mM) for another 24 h. Equal amounts of proteins were subjected to Western blot analysis for the expression of HO1 and NQO1. Fold changes were determined after normalizing with loading control GAPDH. A representative blot from three independent analyses is shown (a). The HO1 levels in the cell lysates were determined by ELISA (b). The mRNA levels of the HO1 gene in Thp1 cells were determined by RT-PCR as described in Section 2 (c). SOD and catalase activities were analyzed in Thp1 cell lysates by using specific kits as per the manufacturer’s instructions (d and e). Data represent mean ± SD (n = 5). *p < 0.01 versus control; #p < 0.05 when compared with the HG-treated group or the Fidarestat alone-treated group.
significant differences in the phosphorylation of AMPK-α1. These results suggest that by regulating the Nrf2-mediated AMPK-α1, AR inhibitor could modulate hyperglycemic stress in Thp1 cells.

4. Discussion

We have shown previously that pretreatment with AR inhibitors prevents cytokine-, chemokine-, HG-, and LPS-induced hyperglycemic stress in Thp1 cells.
inflammatory response mediated by NF-κB in various cellular studies [12–15]. Further, AR inhibitors prevent NF-κB-mediated proinflammatory pathways in vitro and in vivo models of hyperglycemia [12, 16]. However, it is not clear how pretreatment with AR inhibitors prepares cells against oxidative stress and activates Nrf2-mediated anti-inflammatory pathways. In this study, we have demonstrated that fidarestat induces Nrf2-mediated antioxidative and anti-inflammatory pathways in Thp1 monocytic cells. Further, fidarestat also augmented the HG-induced expression of Nrf2 and its downstream targets. These results suggest that preincubation with AR inhibitors prepares the cells to defend against pathological effects of hyperglycemia.

Nrf2 transcription factor regulates the expression of a number of cytoprotective antioxidative genes including SOD, catalase, GSTs, AR, HO1, NQO1, and so forth [9, 10]. Several studies indicate that antioxidants overexpress the Nrf2 pathway as a defense mechanism against various oxidative insults including hyperglycemia [17, 18]. Further, antioxidants such as flavonoids, triterpenoids, quinols, and tBHQ increase the activation of Nrf2 and protect against diabetes-induced nephropathy [19–23]. In addition, Nrf2 null mice are susceptible to the STZ-induced kidney injury [24]. Another study indicates that sulforaphane prevents metabolic dysfunction in hyperglycemia by increasing the expression of the Nrf2 pathway in human endothelial cells [25, 26]. Similarly, curcumin has been shown to decrease insulin resistance, improve pancreatic cell function, and reduce hyperglycemia-induced inflammatory response and complications by activating the Nrf2 pathway [27–29]. These studies suggest the significance of Nrf2 activation in diabetes complications. Consistent with these studies, our current data also suggest that treatment of Thp1 cells with fidarestat augmented the HG-induced Nrf2 activity indicating that fidarestat increases antioxidative balance in the cells and thereby regulates HG-induced cell viability. Furthermore, we have evaluated the effect of fidarestat on HG-induced Thp1 cell viability in Nrf2-ablated cells. Our results demonstrate that AR inhibitor prevented the HG-induced cell death in control cells but not in Nrf2-ablated cells suggesting that Nrf2-mediated antioxidative pathways are required for the actions of AR inhibitor.

Increased expression of Nrf2 leads to increased expression of enzymes linked to antioxidative (NQO1, GSTs, catalase, SOD) and anti-inflammatory (HO1, AR) functions that counteract against oxidative insults [10, 30]. HO1 is an anti-inflammatory protein, and its overexpression has been shown to prevent various inflammatory complications including diabetes [31]. Specifically, HO1 has been shown to protect against HG-induced retinal endothelial cells damage and also prevent vascular inflammatory response in hyperglycemia [32–34]. In this study, our results indicate that fidarestat increases the expression of HO1 and augments HG-induced HO1 in Thp1 cells as well as kidney and heart tissues of STZ-induced diabetic mice suggesting that anti-inflammatory activities of AR inhibition may be through activation of HO1. In addition, our studies also suggest that AR inhibitor increases the expression of SOD and catalase in Thp1 cells and HO1 and NQO1 proteins in STZ-induced diabetic mice heart and kidney tissues, indicating that AR inhibition prevents hyperglycemia-induced oxidative stress by overexpressing various antioxidative enzymes. Since activation of AMPK has been shown to be involved in the regulation of Nrf2 pathway [35], we have also examined the effect of AR inhibitor fidarestat on HG-induced changes in the phosphorylation of AMPK-α1 in Thp1 cells. Our results suggest that pretreatment with fidarestat stimulates phosphorylation of AMPK-α1 in HG-induced Thp1 cells. However, fidarestat pretreatment has no effect on the AMPK-α1 activation in Nrf2-ablated cells.

In conclusion, we have shown that AR inhibitor fidarestat prevents HG-induced Thp1 cell death by induction of Nrf2 expression; DNA binding activity; and expression of HO1, NQO1, SOD, and catalase via activation of AMPK-α1. This suggests that AR inhibition prevents hyperglycemia-induced complications by upregulating anti-inflammatory pathways in various cellular models. Furthermore, the expression of antioxidant enzymes was increased in both HG and AR inhibitor pretreatment conditions, suggesting a synergistic effect of AR inhibition in dampening oxidative stress. These findings provide a potential therapeutic strategy to mitigate diabetes complications through the activation of the Nrf2 pathway.
Nrf2 pathway in addition to downregulating the proinflammatory NF-κB pathway.

**Abbreviations**

AR: Aldose reductase  
FBS: Fetal bovine serum  
Fid: Fidarestat  
HG: High glucose  
HO1: Hemeoxygenase 1  
NQO1: NAD(P)H-quinone dehydrogenase 1  
Nrf2: Nuclear factor erythroid 2- (NF-E2-) related factor 2  
MTT: 3-(4,5-Dimethylthiazol-2-YL)-2,5-diphenyltetrazolium bromide  
SOD: Superoxide dismutase  
STZ: Streptozotocin.

**Conflicts of Interest**

Authors declare no conflict of interest.

**Acknowledgments**

This study was supported by the funding from NIH/NIDDK, grant DK104786.

**References**

[1] P. Geraldes, J. Hiraoka-Yamamoto, M. Matsumoto et al., "Activation of PKC-δ and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy," *Nature Medicine*, vol. 15, no. 11, pp. 1298–1306, 2009.

[2] V. Busik, S. Mohr, and M. B. Grant, "Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators," *Diabetes*, vol. 57, no. 7, pp. 1952–1965, 2008.

[3] S. K. Srivastava, K. V. Ramana, and A. Bhatnagar, "Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options," *Endocrine Reviews*, vol. 26, no. 3, pp. 380–392, 2005.

[4] K. V. Ramana, "Aldose reductase: new insights for an old enzyme," *Biomolecular Concepts*, vol. 2, no. 1-2, 2011.

[5] K. V. Ramana and S. K. Srivastava, "Aldose reductase: a novel therapeutic target for inflammatory pathologies," *The International Journal of Biochemistry & Cell Biology*, vol. 42, no. 1, pp. 17–20, 2010.

[6] K. V. Ramana, "Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells," *Journal of Biological Chemistry*, vol. 277, no. 35, pp. 32063–32070, 2002.

[7] K. V. Ramana, B. Friedrich, S. Srivastava, A. Bhatnagar, and S. K. Srivastava, "Activation of nuclear factor-B by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase," *Diabetes*, vol. 53, no. 11, pp. 2910–2920, 2004.

[8] S. Srivastava, K. V. Ramana, R. Tamamali, S. K. Srivastava, and A. Bhatnagar, "Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells," *Diabetes*, vol. 55, no. 4, pp. 901–910, 2006.

[9] T. Nguyen, P. Nioi, and C. B. Pickett, "The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress," *Journal of Biological Chemistry*, vol. 284, no. 20, pp. 13291–13295, 2009.

[10] Q. Ma, "Role of Nrf2 in oxidative stress and toxicity," *Annual Review of Pharmacology and Toxicology*, vol. 53, no. 1, pp. 401–426, 2013.

[11] R. Tamamali, A. Saxena, S. K. Srivastava, and K. V. Ramana, "Aldose reductase inhibition prevents hyperoxia-induced increase in hyperoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cells," *Journal of Biological Chemistry*, vol. 286, no. 27, pp. 24089–24100, 2011.

[12] K. V. Ramana, B. Friedrich, R. Tamamali, M. B. West, A. Bhatnagar, and S. K. Srivastava, "Requirement of aldose reductase for the hyperglycemic activation of protein kinase C and formation of diacylglycerol in vascular smooth muscle cells," *Diabetes*, vol. 54, no. 3, pp. 818–829, 2005.

[13] M. Shoeb, U. C. S. Yadav, S. K. Srivastava, and K. V. Ramana, "Inhibition of aldose reductase prevents endotoxin-induced inflammation by regulating the arachidonic acid pathway in murine macrophages," *Free Radical Biology and Medicine*, vol. 51, no. 9, pp. 1686–1696, 2011.

[14] S. K. Srivastava, U. C. S. Yadav, A. B. M. Reddy et al., "Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders," *Chemico-Biological Interactions*, vol. 191, no. 1–3, pp. 330–338, 2011.

[15] S. Pandey, S. K. Srivastava, and K. V. Ramana, "A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases," *Expert Opinion on Investigational Drugs*, vol. 21, no. 3, pp. 329–339, 2012.

[16] W. H. Tang, K. A. Martin, and J. Hwa, "Aldose reductase, oxidative stress, and diabetic mellitus," *Frontiers in Pharmacology*, vol. 3, 2012.

[17] J. B. de Haan, "Nrf2 activators as attractive therapeutics for diabetic nephropathy," *Diabetes*, vol. 60, no. 11, pp. 2683–2684, 2011.

[18] B. Li, S. Liu, L. Miao, and L. Cai, "Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy," *Experimental Diabetes Research*, vol. 2012, pp. 1–7, 2012.

[19] K. Liby, "The synthetic triterpenoids, CDDO and CDDO-Mexidazole, are potent inducers of Heme oxygenase-1 and Nrf2/ARE signaling," *Cancer Research*, vol. 65, no. 11, pp. 4789–4798, 2005.

[20] R. K. Thimmulappa, R. J. Fuchs, D. Malhotra et al., "Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils," *Antioxidants & Redox Signaling*, vol. 9, no. 11, pp. 1963–1970, 2007.

[21] D. P. W. Wong, G. Wells, and T. Hagen, "Heteroaromatic 4-arylquinolines are novel inducers of nuclear factor-erythroid 2-related factor 2 (Nrf2)," *European Journal of Pharmacology*, vol. 643, no. 2-3, pp. 188–194, 2010.

[22] H. Li, L. Zhang, F. Wang et al., "Attenuation of glomerular injury in diabetic mice with tert-butyldihydroquinone through nuclear factor erythroid 2-related factor 2-dependent antioxidant gene activation," *American Journal of Nephrology*, vol. 33, no. 4, pp. 289–297, 2011.

[23] Y. Yang, G. Chen, X. Cheng et al., "Therapeutic potential of digitoxavone on diabetic nephropathy: nuclear factor erythroid
2-related factor 2-dependent anti-oxidant and anti-inflammatory effect,” *Scientific Reports*, vol. 5, no. 1, 2015.

[24] T. Jiang, Z. Huang, Y. Lin, Z. Zhang, D. Fang, and D. D. Zhang, “The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy,” *Diabetes*, vol. 59, no. 4, pp. 850–860, 2010.

[25] M. Xue, Q. Qian, A. Adaikalakoteswari, N. Rabbani, R. Babaei-Jadidi, and P. J. Thornalley, “Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease,” *Diabetes*, vol. 57, no. 10, pp. 2809–2817, 2008.

[26] Y. Bai, X. Wang, S. Zhao, C. Ma, J. Cui, and Y. Zheng, “Sulforaphane protects against cardiovascular disease via Nrf2 activation,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, pp. 1–13, 2015.

[27] Z. Ghorbani, A. Hekmatdoost, and P. Mirmiran, “Anti-hyperglycemic and insulin sensitizer effects of turmeric and its principle constituent curcumin,” *International Journal of Endocrinology and Metabolism*, vol. 12, no. 4, 2014.

[28] Y. Masuda, N. D. Vaziri, S. Li et al., “The effect of Nrf2 pathway activation on human pancreatic islet cells,” *PLoS One*, vol. 10, no. 6, p. e0131012, 2015.

[29] D. Zhang, M. Fu, S. H. Gao, and J. L. Liu, “Curcumin and diabetes: a systematic review,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, pp. 1–16, 2013.

[30] E. Kang, G. Kim, H. Kim et al., “Nrf2 regulates curcumin-induced aldose reductase expression indirectly via nuclear factor-κB,” *Pharmacological Research*, vol. 58, no. 1, pp. 15–21, 2008.

[31] G. Negi, V. Nakkina, P. Kamble, and S. S. Sharma, “Heme oxygenase-1, a novel target for the treatment of diabetic complications: focus on diabetic peripheral neuropathy,” *Pharmacological Research*, vol. 102, pp. 158–167, 2015.

[32] Á. F. Castilho, C. A. Aveleira, E. C. Leal et al., “Heme oxygenase-1 protects retinal endothelial cells against high glucose- and oxidative/nitrosative stress-induced toxicity,” *PLoS One*, vol. 7, no. 8, p. e42428, 2012.

[33] M. Li, D. H. Kim, P. L. Tsenovoy et al., “Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance,” *Diabetes*, vol. 57, no. 6, pp. 1526–1535, 2008.

[34] A. Saad, H. Ibrahim, W. Nazmy, and A. Hussein, “Induction of heme oxygenase-1 improves glucose tolerance and enhances insulin sensitivity in obese diabetic rats,” *Journal of Advances in Medical and Pharmaceutical Sciences*, vol. 10, no. 3, pp. 1–11, 2016.

[35] M. S. Joo, W. D. Kim, K. Y. Lee, J. H. Kim, J. H. Koo, and S. G. Kim, “AMPK facilitates nuclear accumulation of Nrf2 by phosphorylating at serine 550,” *Molecular and Cellular Biology*, vol. 36, no. 14, pp. 1931–1942, 2016.